https://www.selleckchem.com/pr....oducts/cbl0137-cbl-0
s after aSAH. Such quantitative analysis suggests that GCE may be more impactful to younger patients with SAH. We assessed the outcomes of dabigatran versus aspirin in a prespecified subgroup analysis of East Asian patients with embolic stroke of undetermined source in the RE-SPECT ESUS trial (Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source).
Curtir
Comentario
Compartilhar
